Top-Rated StocksTop-RatedNASDAQ:IRON Disc Medicine Opco (IRON) Stock Forecast, Price & News $49.00 +0.02 (+0.04%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$47.52▼$49.5050-Day Range$45.00▼$55.9952-Week Range$11.80▼$57.70Volume133,571 shsAverage Volume247,010 shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$53.78 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Disc Medicine Opco MarketRank™ ForecastAnalyst RatingBuy3.10 Rating ScoreUpside/Downside9.8% Upside$53.78 Price TargetShort InterestHealthy2.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 8 Articles This WeekInsider TradingSelling Shares$77.79 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.47) to ($3.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.38 out of 5 starsMedical Sector908th out of 966 stocksPharmaceutical Preparations Industry427th out of 451 stocks 1.6 Analyst's Opinion Consensus RatingDisc Medicine Opco has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $53.78, Disc Medicine Opco has a forecasted upside of 9.8% from its current price of $49.00.Amount of Analyst CoverageDisc Medicine Opco has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.19% of the outstanding shares of Disc Medicine Opco have been sold short.Short Interest Ratio / Days to CoverDisc Medicine Opco has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Disc Medicine Opco has recently decreased by 6.24%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDisc Medicine Opco does not currently pay a dividend.Dividend GrowthDisc Medicine Opco does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IRON. Previous Next 1.9 News and Social Media Coverage News SentimentDisc Medicine Opco has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Disc Medicine Opco this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for IRON on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Disc Medicine Opco to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Disc Medicine Opco insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,786,351.00 in company stock.Percentage Held by InsidersOnly 4.71% of the stock of Disc Medicine Opco is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Disc Medicine Opco are expected to decrease in the coming year, from ($3.47) to ($3.90) per share.Price to Book Value per Share RatioDisc Medicine Opco has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Disc Medicine Opco (NASDAQ:IRON) StockDisc Medicine Opco Inc, together with its subsidiaries, operates as a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company builds a portfolio of fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. It also develops bitopertin for the treatment of erythropoietic porphyrias, erythropoietic protoporphyria, and X-linked protoporphyria. In addition, the company develops DISC-0974 for the treatment of chronic kidney disease; MWTX-003 for the treatment of polycythemia vera, and other hematologic disorders; and DISC-0998 for the treatment of anemia associated with inflammatory. The company is based in Watertown, Massachusetts.Read More IRON Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IRON Stock News HeadlinesSeptember 20, 2023 | finance.yahoo.comDisc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia VeraSeptember 20, 2023 | americanbankingnews.comDisc Medicine Opco Inc (NASDAQ:IRON) Short Interest Down 6.2% in AugustSeptember 22, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 19, 2023 | americanbankingnews.comVenture Fund X. L.P. Atlas Sells 94,440 Shares of Disc Medicine Opco Inc (NASDAQ:IRON) StockSeptember 17, 2023 | americanbankingnews.comDisc Medicine Opco Inc (NASDAQ:IRON) Given Consensus Rating of "Buy" by BrokeragesSeptember 6, 2023 | finance.yahoo.comWith 52% ownership, Disc Medicine Opco Inc (NASDAQ:IRON) boasts of strong institutional backingAugust 30, 2023 | finance.yahoo.comDisc Medicine to Participate in Upcoming Investor ConferencesAugust 22, 2023 | seekingalpha.comDisc Medicine: Rare Disease Developer Derisking ItselfSeptember 22, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."July 27, 2023 | finance.yahoo.comDisc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)July 26, 2023 | finance.yahoo.comHere's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock NowJuly 12, 2023 | investing.comDisc Medicine Inc (IRON)June 22, 2023 | finance.yahoo.comDisc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional SharesJune 13, 2023 | finance.yahoo.comDisc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsJune 12, 2023 | finance.yahoo.comDisc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 9, 2023 | finance.yahoo.comWhy Perfectly Rated Disc Medicine, With A 234% Move This Year, Just Put Up Another Big GainJune 9, 2023 | seekingalpha.comDisc Medicine: Soaring On EPP Data Release, Reality May Bite On Limited Market OpportunityJune 9, 2023 | finance.yahoo.comDisc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 CongressJune 7, 2023 | fool.comDisc Medicine Opco (NASDAQ: IRON)June 1, 2023 | finance.yahoo.comWhy Shares of Disc Medicine Opco Climbed This WeekMay 31, 2023 | finance.yahoo.comDisc Medicine to Participate in the Jefferies Healthcare ConferenceMay 19, 2023 | msn.comRaymond James Initiates Coverage of Disc Medicine (IRON) with Outperform RecommendationMay 15, 2023 | finance.yahoo.comDisc Medicine Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | finance.yahoo.comDisc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 CongressMay 10, 2023 | finance.yahoo.comIs a Surprise Coming for Disc Medicine (IRON) This Earnings Season?May 5, 2023 | finance.yahoo.comDisc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be SustainableMay 4, 2023 | finance.yahoo.comDisc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should KnowSee More Headlines Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine Opco and its competitors with MarketBeat's FREE daily newsletter. Email Address IRON Company Calendar Last Earnings8/11/2023Today9/21/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRON CUSIPN/A CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees55Year FoundedN/APrice Target and Rating Average Stock Price Forecast$53.78 High Stock Price Forecast$75.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+9.8%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.88% Return on Assets-28.31% Debt Debt-to-Equity RatioN/A Current Ratio39.42 Quick Ratio39.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.15 per share Price / Book4.83Miscellaneous Outstanding Shares22,878,000Free Float21,800,000Market Cap$1.12 billion OptionableNot Optionable Beta-0.08 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. John D. Quisel Esq. (Age 52)J.D., Ph.D., CEO, Pres, Sec. & Director Comp: $750.12kMs. Joanne Bryce CPA (Age 56)Chief Financial Officer Comp: $539.32kMr. Jonathan Yu (Age 42)Chief Bus. Officer Comp: $539.32kDr. William Jacob Savage M.D. (Age 48)Ph.D., Chief Medical Officer Comp: $571.95kDr. Brian MacDonald ChB (Age 63)MB, Ph.D., Founder & Chief Innovation Officer Dr. Rahul Khara J.D. (Age 41)Pharm.D., Gen. Counsel, Compliance Officer & Sec. Mr. Srikanth Venkatraman Ph.D.Sr. VP & Head of ChemistryMs. Hua Yang Ph.D.Sr. VP of Nonclinical Devel.More ExecutivesKey CompetitorsGeronNASDAQ:GERNSyndax PharmaceuticalsNASDAQ:SNDXMirum PharmaceuticalsNASDAQ:MIRMMannKindNASDAQ:MNKDRevance TherapeuticsNASDAQ:RVNCView All CompetitorsInsiders & InstitutionsBarclays PLCSold 4,066 shares on 9/21/2023Ownership: 0.007%Venture Fund X L.P. AtlasSold 2,115 sharesTotal: $112,560.30 ($53.22/share)Venture Fund X L.P. AtlasSold 94,440 sharesTotal: $5.01 M ($53.05/share)Davidson Kempner Capital Management LPBought 90,000 shares on 9/12/2023Ownership: 0.000%Joanne BryceSold 1,000 sharesTotal: $52,990.00 ($52.99/share)View All Insider TransactionsView All Institutional Transactions IRON Stock - Frequently Asked Questions Should I buy or sell Disc Medicine Opco stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Disc Medicine Opco in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IRON shares. View IRON analyst ratings or view top-rated stocks. What is Disc Medicine Opco's stock price forecast for 2023? 10 brokerages have issued 12-month target prices for Disc Medicine Opco's shares. Their IRON share price forecasts range from $30.00 to $75.00. On average, they anticipate the company's stock price to reach $53.78 in the next year. This suggests a possible upside of 9.8% from the stock's current price. View analysts price targets for IRON or view top-rated stocks among Wall Street analysts. How have IRON shares performed in 2023? Disc Medicine Opco's stock was trading at $17.95 on January 1st, 2023. Since then, IRON shares have increased by 173.0% and is now trading at $49.00. View the best growth stocks for 2023 here. Are investors shorting Disc Medicine Opco? Disc Medicine Opco saw a decline in short interest in August. As of August 31st, there was short interest totaling 502,000 shares, a decline of 6.2% from the August 15th total of 535,400 shares. Based on an average daily volume of 234,400 shares, the short-interest ratio is currently 2.1 days. View Disc Medicine Opco's Short Interest. When is Disc Medicine Opco's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our IRON earnings forecast. How were Disc Medicine Opco's earnings last quarter? Disc Medicine Opco Inc (NASDAQ:IRON) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.12. What ETFs hold Disc Medicine Opco's stock? ETFs with the largest weight of Disc Medicine Opco (NASDAQ:IRON) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What is Disc Medicine Opco's stock symbol? Disc Medicine Opco trades on the NASDAQ under the ticker symbol "IRON." Who are Disc Medicine Opco's major shareholders? Disc Medicine Opco's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Bain Capital Life Sciences Investors LLC (6.73%), Perceptive Advisors LLC (3.75%), Citadel Advisors LLC (3.29%), BlackRock Inc. (2.54%), Polar Capital Holdings Plc (2.15%) and Rock Springs Capital Management LP (1.84%). Insiders that own company stock include Brian Richard Macdonald, Holdings A/S Novo, Joanne Bryce, Kevin Bitterman, Venture Fund X LP Atlas and William Jacob Savage. View institutional ownership trends. How do I buy shares of Disc Medicine Opco? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Disc Medicine Opco's stock price today? One share of IRON stock can currently be purchased for approximately $49.00. How much money does Disc Medicine Opco make? Disc Medicine Opco (NASDAQ:IRON) has a market capitalization of $1.12 billion. How can I contact Disc Medicine Opco? Disc Medicine Opco's mailing address is 297 Boston Post Road #248, Wayland MA, 01778. The official website for the company is www.discmedicine.com. The company can be reached via phone at 617-401-4400 or via email at ir@geminitherapeutics.com. This page (NASDAQ:IRON) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine Opco Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.